Review Article
Oral Anticoagulant Therapy in Patients Receiving Haemodialysis: Is It Time to Abandon It?
Table 3
Mortality risk in haemodialysis patients with atrial fibrillation treated with warfarin.
| Study | Population () | Period (y) | Mortality (HR) |
| Knoll et al. [36] | —235 pts | 3 years | HR—0.80 (95% CI 0.28–2.29, ) |
| Chan et al. [37] | —1671 pts | 1 year | HR—1.10 (0.94–1.30) |
|
Wizemann et al. [38] | —17513 pts (AF—12.5%) | 7 years | All ages: HR—1.16 (95% CI 1.08–1.25, ) | Age < 65: HR—1.29 (95% CI 0.45–3.68, ) | Age 65–75: HR—1.35 (95% CI 0.69–2.63, ) | Age > 75: HR—2.17 (95% CI 1.04–4.53, ) |
| Chan et al. [39] | —41425 pts | 11 years | | Warfarin—8.3% | HR—1.73 (95% CI 1.62–1.85) | Clopidogrel—10% | HR—1.50 (95% CI 1.39–1.62) | Acetylsalicylic acid—30.4% | HR—1.17 (95% CI 1.12–1.22) | Acetylsalicylic acid and warfarin—8% | HR—1.11 (95% CI 1.03–1.86) |
|
|
HR: hazard ratio, CI: confidence interval, : number of patients.
|